Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer BioSpaceA triplet regimen comprising Merck's Welireg and PD-1 blockbuster Keytruda and Eisai's Lenvima flopped in a Phase 3 renal cell carcinoma trial.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioSpace A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo Nordisk preps filings for sickle cell drug etavopivatNext: Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
